Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Rifabutin Articles

11 NCEs added to Japan's NHI drugprice lis, inc Erbitux, Macugen and Nazonex

8 September 2008

Gilead's Vistide Cleared By CPMP

6 January 1997

Malaysian Drug Regulation Update

1 July 1996

USA Clears Pfizer's Zithromax For MAC

24 June 1996

Triple Therapies For HIV Provide Encouraging Data

5 February 1996

Marriage Of Pharmacia And Upjohn Will Create New $13 Bill Drug Group

4 September 1995

Pharmacia Pipeline Promises Future Growth

20 March 1995

Mycobutin Enters TB Prophylaxis Trials

27 February 1995

Pharmacia's Sales Decline But Profits Rise

21 November 1994

2.8 Bill Kroner Interim Profits For Pharmacia

5 September 1994

RIFABUTIN LAUNCHED IN FRANCE

9 May 1994

MYCOBUTIN EFFECTIVE IN MAC PREVENTION

27 September 1993

MYCOBUTIN RECOMMENDED FOR MAC

2 August 1993

ADRIA SMITHKLINE AGREEMENT

26 July 1993

MYCOBUTIN PROMOTION DEAL

17 May 1993

MONTEDISON AND PROCORDIA DEAL

29 March 1993

MONTECATINI 1992 RESULTS

15 February 1993

NEW CHEMICAL ENTITIES LAUNCHED IN 1992

1 February 1993

FDA APPROVES 26 NEWDRUGS IN 1992

25 January 1993

FDA YEAR-END DRUG APPROVALS ROLL-OUT

4 January 1993

PANEL BACKS TWO AIDS DRUGS IN USA

5 October 1992

MYCOBUTIN: US APPROVAL DELAYED

15 June 1992

"ROLLING" NDA FOR ADRIA'S RIFABUTIN

13 April 1992

ADRIA EXTENDS RIFABUTIN IND

23 March 1992

Showing 1-24 of 24 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS